Novel indeno[1,2-b]indoloquinones as inhibitors of the human protein kinase CK2 with antiproliferative activity towards a broad panel of cancer cell lines

Biochemical and Biophysical Research Communications

Volumn 424, Issue 1, 2012, Pages 71-75

  Hundsdörfer, Claas ^a   Hemmerling, Hans Jörg ^b   Hamberger, Janina ^c   Le Borgne, Marc ^d   Bednarski, Patrick ^c   Götz, Claudia ^e   Totzke, Frank ^f   Jose, Joachim ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d UNIVERSITÉ LYON 1   (France)

^e SAARLAND UNIVERSITY   (Germany)

^f PROQINASE GMBH   (Germany)

Author keywords

ARK5; Cancer; CK2; FLT3; Inhibitors; Protein kinase

Indexed keywords

5 BENZYL 5H INDENO[1,2 B]INDOLE 6,9,10 TRIONE; 5 ISOPROPYL 5H INDENO[1,2 B]INDOLE 6,9,10 TRIONE; CASEIN KINASE II; CD135 ANTIGEN; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; QUINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CASEIN KINASE II; CELL LINE, TUMOR; HUMANS; INDENES; INDOLEQUINONES; INDOLES; INHIBITORY CONCENTRATION 50; PROTEIN KINASE INHIBITORS;

EID: 84864076597     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.06.068     Document Type: Article

References (40)

1. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
2. Lindberg R.A., Quinn A.M., Hunter T. Dual-specificity protein kinases: will any hydroxyl do?. Trends Biochem. Sci. 1992, 17:114-119.
3. Vilk G., Weber J.E., Turowec J.P., Duncan J.S., Wu C., Derksen D.R., Zien P., Sarno S., Donella-Deana A., Lajoie G., Pinna L.A., Li S.S.C., Litchfield D.W. Protein kinase CK2 catalyzes tyrosine phosphorylation in mammalian cells. Cell. Signal. 2008, 20:1942-1951.
4. Salvi M., Sarno S., Cesaro L., Nakamura H., Pinna L.A. Extraordinary pleiotropy of protein kinase CK2 revealed by weblogo phosphoproteome analysis. Biochim. Biophys. Acta, Mol. Cell Res. 2009, 1793:847-859.
5. Niefind K., Putter M., Guerra B., Issinger O.-G., Schomburg D. GTP plus water mimic ATP in the active site of protein kinase CK2. Nat. Struct. Mol. Biol. 1999, 6:1100-1103.
6. Faust M., Montenarh M. Subcellular localization of protein kinase CK2. Cell Tissue Res. 2000, 301:329-340.
7. Guerra B., Issinger O.-G. Protein kinase CK2 in human diseases. Curr. Med. Chem. 2008, 15:1870-1886.
8. Trembley J., Wang G., Unger G., Slaton J., Ahmed K. Protein kinase CK2 in health and disease. Cell. Mol. Life Sci. 2009, 66:1858-1867.
9. Ahmad K.A., Wang G., Unger G., Slaton J., Ahmed K. Protein kinase CK2 - a key suppressor of apoptosis. Adv. Enzyme Regul. 2008, 48:179-187.
10. Ruzzene M., Pinna L.A. Addiction to protein kinase CK2: a common denominator of diverse cancer cells?. Biochim. Biophys. Acta, Proteins Proteomics 1804, 2010:499-504.
11. Wang G., Unger G., Ahmad K.A., Slaton J.W., Ahmed K. Downregulation of CK2 induces apoptosis in cancer cells - a potential approach to cancer therapy. Mol. Cell. Biochem. 2005, 274:77-84.
12. Hundsdörfer C., Hemmerling H.-J., Götz C., Totzke F., Bednarski P., Le Borgne M., Jose J. Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors. Bioorg. Med. Chem. 2012, 20:2282-2289.
13. Kashyap M., Das D., Preet R., Mohapatra P., Satapathy S.R., Siddharth S., Kundu C.N., Guchhait S.K. Scaffold hybridization in generation of indenoindolones as anticancer agents that induce apoptosis with cell cycle arrest at G2/M phase. Bioorg. Med. Chem. Lett. 2012, 22:2474-2479.
14. Hemmerling H.J., Reiss G. Partially Saturated Indeno[1,2-b]indole Derivatives via Deoxygenation of Heterocyclic alpha-Hydroxy-N, O-hemiaminals. Synthesis 2009, 985-999.
15. Olgen S., Gotz C., Jose J. Synthesis and biological evaluation of 3-(substituted-benzylidene)-1,3-dihydro-indolin derivatives as human protein kinase CK2 and p60(c-Src) tyrosine kinase inhibitors. Biol. Pharm. Bull. 2007, 30:715-718.
16. Saczewski F., Reszka P., Gdaniec M., Grunert R., Bednarski P.J. Synthesis, x-ray crystal structures, stabilities, and in vitro cytotoxic activities of new heteroarylacrylonitriles. J. Med. Chem. 2004, 47:3438-3449.
17. Bracht K., Boubakari, Grunert R., Bednarski P.J. Correlations between the activities of 19 anti-tumor agents and the intracellular glutathione concentrations in a panel of 14 human cancer cell lines: comparisons with the National Cancer Institute data. Anticancer Drugs 2006, 17:41-51.
18. Aly A.H., Edrada-Ebel R., Indriani I.D., Wray V., Müller W.E.G., Totzke F., Zirrgiebel U., Schächtele C., Kubbutat M.H.G., Lin W.H., Proksch P., Ebel R. Cytotoxic metabolites from the fungal endophyte Alternaria sp. and their subsequent detection in its host plant polygonum senegalense. J. Nat. Prod. 2008, 71:972-980.
19. Edstrom E.D. Synthesis of 4-Hydroxy-3-Substituted Indoles and Indolequinones Via an 3-Acetyloxy-4-Oxo-4,5,6,7-Tetrahydroindole Intermediate. Synlett 1995, 49-50.
20. Sarno S., de Moliner E., Ruzzene M., Pagano M.A., Battistutta R., Bain J., Fabbro D., Schoepfer J., Elliott M., Furet P., Meggio F., Zanotti G., Pinna L.A. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). Biochem. J. 2003, 374:639-646.
21. Cadenas E. Biochemistry of oxygen toxicity. Annu. Rev. Biochem. 1989, 58:79-110.
22. http://www.molinspiration.com/cgi-bin/properties, accesion date: March 1, 2012.
23. http://preadmet.bmdrc.org, accesion date: June 1, 2012.
24. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46:3-26.
25. Clark D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J. Pharm. Sci. 1999, 88:807-814.
26. Ertl P., Rohde B., Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 2000, 43:3714-3717.
27. Yazdanian M., Glynn S.L., Wright J.L., Hawi A. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm. Res. 1998, 15:1490-1494.
28. Suzuki A., Kusakai G.-I., Kishimoto A., Lu J., Ogura T., Lavin M.F., Esumi H. Identification of a novel protein kinase mediating Akt survival signaling to the ATM protein. J. Biol. Chem. 2003, 278:48-53.
29. Suzuki A., Kusakai G.-I., Kishimoto A., Lu J., Ogura T., Esumi H. ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation. Oncogene 2003, 22:6177-6182.
30. da Silva G., Evangelista A., Magalhães D., Macedo C., Búfalo M., Sakamoto-Hojo E., Passos G., Salvadori D. Expression of genes related to apoptosis, cell cycle and signaling pathways are independent of TP53 status in urinary bladder cancer cells. Mol. Biol. Rep. 2011, 38:4159-4170.
31. Kusakai G., Suzuki A., Ogura T., Kaminishi M., Esumi H. Strong association of ARK5 with tumor invasion and metastasis. J. Exp. Clin. Cancer Res. 2004, 23:263-268.
32. Suzuki A., Iida S., Kato-Uranishi M., Tajima E., Fenghuang Z., Hanamura I., Yongsheng H., Ogura T., Takahashi S., Ueda R., Barlogie B., Shaughnessy J., Esumi H. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene 2005, 24:6936-6944.
33. Nambaru P.K., Hübner T., Köck K., Mews S., Grube M., Payen L., Guitton J., Sendler M., Jedlitschky G., Rimmbach C., Rosskopf D., Kowalczyk D.W., Kroemer H.K., Weiss F.U., Mayerle J., Lerch M.M., Ritter C.A. Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. Drug Metab. Dispos. 2011, 39:132-139.
34. Serve H. Expression and function of Flt3/flk2 in human tumor cell lines. Int. J. Oncol. 1999, 14:765-770.
35. Stirewalt D.L., Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer 2003, 3:650-665.
36. Carow C., Levenstein M., Kaufmann S., Chen J., Amin S., Rockwell P., Witte L., Borowitz M., Civin C., Small D. Expression of the hematopoietic growth factor receptor FLT3 (STK- 1/Flk2) in human leukemias. Blood 1996, 87:1089-1096.
37. Levis M., Small D. Novel FLT3 tyrosine kinase inhibitors. Expert Opin. Invest. Drugs 2003, 12:1951-1962.
38. Kindler T., Lipka D.B., Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010, 116:5089-5102.
39. Gilliland D.G., Griffin J.D. Role of FLT3 in leukemia. Curr. Opin. Hematol. 2002, 9:274-281.
40. Zarrinkar P.P., Gunawardane R.N., Cramer M.D., Gardner M.F., Brigham D., Belli B., Karaman M.W., Pratz K.W., Pallares G., Chao Q., Sprankle K.G., Patel H.K., Levis M., Armstrong R.C., James J., Bhagwat S.S. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia. Blood 2009, 114:2984-2992.